Improving early diagnosis of symptomatic cancer

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

StandardStandard

Improving early diagnosis of symptomatic cancer. / Hamilton, Willie; Walter, Fiona M.; Rubin, Greg et al.
Yn: Nature Reviews Clinical Oncology, Cyfrol 13, Rhif 12, 12.2016, t. 740-749.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

Hamilton, W, Walter, FM, Rubin, G & Neal, R 2016, 'Improving early diagnosis of symptomatic cancer', Nature Reviews Clinical Oncology, cyfrol. 13, rhif 12, tt. 740-749. https://doi.org/10.1038/nrclinonc.2016.109

APA

Hamilton, W., Walter, F. M., Rubin, G., & Neal, R. (2016). Improving early diagnosis of symptomatic cancer. Nature Reviews Clinical Oncology, 13(12), 740-749. https://doi.org/10.1038/nrclinonc.2016.109

CBE

Hamilton W, Walter FM, Rubin G, Neal R. 2016. Improving early diagnosis of symptomatic cancer. Nature Reviews Clinical Oncology. 13(12):740-749. https://doi.org/10.1038/nrclinonc.2016.109

MLA

Hamilton, Willie et al. "Improving early diagnosis of symptomatic cancer". Nature Reviews Clinical Oncology. 2016, 13(12). 740-749. https://doi.org/10.1038/nrclinonc.2016.109

VancouverVancouver

Hamilton W, Walter FM, Rubin G, Neal R. Improving early diagnosis of symptomatic cancer. Nature Reviews Clinical Oncology. 2016 Rhag;13(12):740-749. Epub 2016 Gor 26. doi: 10.1038/nrclinonc.2016.109

Author

Hamilton, Willie ; Walter, Fiona M. ; Rubin, Greg et al. / Improving early diagnosis of symptomatic cancer. Yn: Nature Reviews Clinical Oncology. 2016 ; Cyfrol 13, Rhif 12. tt. 740-749.

RIS

TY - JOUR

T1 - Improving early diagnosis of symptomatic cancer

AU - Hamilton, Willie

AU - Walter, Fiona M.

AU - Rubin, Greg

AU - Neal, Richard

PY - 2016/12

Y1 - 2016/12

N2 - Much time, effort and investment goes into the diagnosis of symptomatic cancer, with the expectation that this approach brings clinical benefits. This investment of resources has been particularly noticeable in the UK, which has, for several years, appeared near the bottom of international league tables for cancer survival in economically developed countries. This Review examines expedited diagnosis of cancer from four perspectives. The first examines the potential for benefits from expedited diagnosis of symptomatic cancer. Limited evidence from clinical trials is available, but the considerable observational evidence suggests benefits can be obtained from this approach. The second perspective considers how expedited diagnosis can be achieved. We concentrate on data from the UK, where extensive awareness campaigns have been conducted, and initiatives in primary care, including clinical decision support, have all occurred during a period of considerable national policy change. The third section considers the most appropriate patients for cancer investigations, and the possible community settings for this. UK national guidance for selection of patients for investigation is discussed. Finally, the health economics of the subject are reviewed, although few studies provide definitive evidence on this topic.

AB - Much time, effort and investment goes into the diagnosis of symptomatic cancer, with the expectation that this approach brings clinical benefits. This investment of resources has been particularly noticeable in the UK, which has, for several years, appeared near the bottom of international league tables for cancer survival in economically developed countries. This Review examines expedited diagnosis of cancer from four perspectives. The first examines the potential for benefits from expedited diagnosis of symptomatic cancer. Limited evidence from clinical trials is available, but the considerable observational evidence suggests benefits can be obtained from this approach. The second perspective considers how expedited diagnosis can be achieved. We concentrate on data from the UK, where extensive awareness campaigns have been conducted, and initiatives in primary care, including clinical decision support, have all occurred during a period of considerable national policy change. The third section considers the most appropriate patients for cancer investigations, and the possible community settings for this. UK national guidance for selection of patients for investigation is discussed. Finally, the health economics of the subject are reviewed, although few studies provide definitive evidence on this topic.

U2 - 10.1038/nrclinonc.2016.109

DO - 10.1038/nrclinonc.2016.109

M3 - Article

VL - 13

SP - 740

EP - 749

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 12

ER -